Live Chat ×
Skip to main content

Maude Abbott 2016

Loading video

This video is currently being processed. It will be ready for viewing shortly.

Please Verify Attendance
Time Remaining:


Lecturer: Stuart J. Schnitt, MD, Beth Israel Deaconess Medical Center, Boston, MA

At the conclusion of this lecture, attendees will be able to:

  1. Describe the essential role of the pathologist in determining the suitability of breast cancer patients for breast conserving therapy
  2. Discuss the current guidelines for lumpectomy margin evaluation
  3. Describe the emerging role of breast cancer molecular subtypes in assessing risk of local recurrence after breast conserving therapy


  • Stuart J. Schnitt, MD

    Stuart J. Schnitt, M.D. is the Chief of Breast Oncologic Pathology for the Dana-Farber/Brigham and Women’s Cancer Center, Associate Director of the Dana-Farber Cancer Institute/Brigham and Women’s Hospital Breast Oncology Program, co-leader of the Dana Farber Harvard Cancer Center Breast Program, Senior Pathologist at Brigham and Women’s Hospital, a Professor of Pathology at Harvard Medical School and an internationally recognized expert in breast pathology.

    Dr. Schnitt did his internship and residency in Anatomic and Clinical Pathology at Beth Israel Hospital in Boston followed by a fellowship in surgical pathology, also at Beth Israel Hospital. He was a faculty member in the Beth Israel Hospital/Beth Israel Deaconess Medical Center Department of Pathology from 1984-2017, including 11 years as Director of Anatomic Pathology and subsequently Vice Chair for Anatomic Pathology. He has published over 350 original articles, review articles, editorials, commentaries, and book chapters, primarily in the area of breast diseases. He has authored a popular breast pathology textbook entitled “Biopsy Interpretation of the Breast”, now its third edition. The first two editions of this book were also published in Chinese. In addition, he is one of the editors of the 4th Edition of the “World Health Organization Classification of Tumours of the Breast”, published in 2012 and is serving as an editor of the upcoming 5th Edition of the “World Health Organization Classification of Tumours of the Breast”.

    He is a Past President of the United States and Canadian Academy of Pathology (2010-2011). Other notable honors include the Arthur Purdy Stout Society of Surgical Pathologists Annual Prize (1999), the Albany Medical College Distinguished Alumnus Award (2014), the Lynn Sage Distinguished Lecturer (2014), the Maude Abbot Lecture at the United States and Canadian Academy of Pathology Annual Meeting (2016), the United States and Canadian Academy of Pathology F.K. Mostofi Distinguished Service Award (2018) and United States and Canadian Academy of Pathology Harvey Goldman Master Teacher Award (2019). He is particularly proud to have been involved in the training of 37 breast pathology fellows since 1995. He has lectured extensively around the world. His research interests and contributions to our understanding of benign breast diseases and breast cancer have been broad, but have largely focused on risk factors for local recurrence in patients with invasive breast cancer and ductal carcinoma in situ treated with breast conserving therapy, benign breast disease and breast cancer risk, and stromal-epithelial interactions in breast tumor progression.